Mind Programme for Women With Breast Cancer (Nationwide Coverage)
The purpose of this research project is to optimize the Mind programme for women with breast cancer, taking into consideration the results from its pilot study, and to testits efficacy and cost-effectiveness through a 3-arm randomized controlled trial
Breast Cancer Female
BEHAVIORAL: Mind Programme|BEHAVIORAL: Support Group
Change from baseline cancer-specific quality of life at post-treatment and 6-month follow-up, EORTC QLQ-C30, Baseline, post-treatment (2 months after baseline) and 6-month follow-up
Change from baseline depressive symptoms and anxiety severity at post-treatment and 6-month follow-up, Hospital Anxiety and Depression Scale, Baseline, post-treatment (2 months after baseline) and 6-month follow-up|Change from baseline psychological flexibility at post-treatment and 6-month follow-up, Comprehensive Assessment of Acceptance and Commitment Therapy Processes, Baseline, post-treatment (2 months after baseline) and 6-month follow-up|Change from baseline self-compassion and mindfulness at post-treatment and 6-month follow-up, Self-Compassion Scale, Baseline, post-treatment (2 months after baseline) and 6-month follow-up|Change from baseline health-related quality of life at post-treatment and 6-month follow-up, EQ-5D-5L, Baseline, post-treatment (2 months after baseline) and 6-month follow-up|Change from baseline consumption of resources and costs in breast cancer at post-treatment and 6-month follow-up, This questionnaire was developed by the research team and adapted from the UK Cancer Costs Questionnaire (UKCC) Version 2.0 to assess the consumption of resources and economic costs associated with breast cancer., Baseline, post-treatment (2 months after baseline) and 6-month follow-up|Major life events - controlling variable, Major Life Events Questionnaire, 6-month follow-up|Sociodemographic and clinical variables - controlling variables, Baseline
The purpose of this research project is to optimize the Mind programme for women with breast cancer, taking into consideration the results from its pilot study, and to testits efficacy and cost-effectiveness through a 3-arm randomized controlled trial